Syncrosome is a preclinical CRO dedicated to in vivo efficacy studies. More than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in vivo efficacy studies to offer better predictability and anticipate clinical results. Syncrosome offer relevant disease models, cutting-edge techniques, specific biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds. We have developed and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers. Our main activities consist in : - In vivo Drug Efficacy Studies for: • Central Nervous System • Cardiovascular and Metabolic disease • Respiratory • Gastroenterology • Dermatology - CNS-PK with a special focus in the study of the Blood Brain Barrier passage and/or Neurotransmitter monitoring. - Early bioavailability studies (PK/PD) on rodents and non-rodents. Beyond sound science, our proactive approach combining pharmacological expertise, appropriate study design, relevant endpoints , performed on relevant and complemental disease models, provide our clients with the most relevant datas. Besides our premium services and track record of success, we pay especial attention to ethics, animal welfare, sustainable development and to the validation of up to date technics. For more information, you can visit our website: www.syncrosome.com Or contact us by phone: +33(0) 495 053 180